Advertisement
Advertisement
AQST
Aquestive Therapeutics, Inc. Common Stock
3.46
USDSponsored
-0.25
-6.61%
Nov 20, 15:59 UTC -5
Closed
After-Market
3.51
+0.05
+1.45%
Aquestive Therapeutics, Inc. Common Stock (AQST) Earnings
AQST Earnings Reports
Positive Surprise Ratio
AQST beat 17 of 34 last estimates.
50%
Next Report
Date of Next Report
Mar 02, 2027
Estimate for Q4 26 (Revenue/ EPS)
$13.97M
/-$0.11
Implied change from Q3 26 (Revenue/ EPS)
+84.84%
/-15.38%
Implied change from Q4 25 (Revenue/ EPS)
+7.32%
/-26.67%
Aquestive Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 03, 2026, AQST reported earnings of -0.13 USD per share (EPS) for Q3 26, missing the estimate of -0.11 USD, resulting in a -10.17% surprise. Revenue reached 7.56 million, compared to an expected 11.24 million, with a -32.75% difference. The market reacted with a -2.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.11 USD, with revenue projected to reach 13.97 million USD, implying an decrease of -15.38% EPS, and increase of 84.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were Aquestive Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Aquestive Therapeutics, Inc. Common Stock reported EPS of -$0.13, missing estimates by -10.17%, and revenue of $7.56M, -32.75% below expectations.
How did the market react to Aquestive Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -2.06%, changed from $3.88 before the earnings release to $3.80 the day after.
When is Aquestive Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2027.
What are the forecasts for Aquestive Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Aquestive Therapeutics, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $13.97M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.